ALNY — Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Net Product Revenues: $851 million, up 103% year-over-year, driven by TTR franchise growth.
• TTR Franchise Revenues: $724 million, representing a 135% increase year-over-year, with U.S. revenues at $543 million (194% growth).
• Collaboration Revenue: $352 million, a significant increase due to a $300 million milestone from Roche related to the ZENITH Phase III trial.
• Gross Margin: 77%, down from 80% in Q3 2024, primarily due to increased royalties.
• Non-GAAP Operating Income: $476 million, a substantial increase compared to the previous year.
• Cash Position: $2.7 billion, impacted by refinancing activities.

2. Strategic Updates and Business Highlights

• TTR Leadership: Continued strong performance from the AMVUTTRA cardiomyopathy launch, with a doubling of patient demand in the U.S.
• Pipeline Advancements: Initiation of two new Phase III trials: ZENITH for zilebesiran in hypertension and TRITON-PN for nucresiran in hATTR-PN.
• Rare Disease Portfolio: Achieved $127 million in sales, reflecting a 14% year-over-year increase.
• International Expansion: Positive early progress in Japan for AMVUTTRA, with launches anticipated in other markets throughout 2026.

3. Forward Guidance and Outlook

• Revised Revenue Guidance: Increased total net product revenue guidance for 2025 to $2.95 billion - $3.05 billion, reflecting a 10% increase at the midpoint.
• TTR Franchise Guidance: Revised to $2.475 billion - $2.525 billion, a 12% increase at the midpoint.
• Operating Expense Guidance: Narrowed to $2.15 billion - $2.2 billion, with expectations to end at the upper end of the range.

4. Bad News, Challenges, or Points of Concern

• Gross Margin Decline: Expected further decrease in gross margin due to rising royalty rates on AMVUTTRA.
• Competitive Pressures: New competition in the hATTR-PN market, although Alnylam maintains strong market share.
• Regulatory Risks: Ongoing subpoena from the U.S. Attorney General regarding government price reporting, which could pose legal and operational challenges.

5. Notable Q&A Insights

• Payer Dynamics: No significant payer headwinds reported; broad coverage for AMVUTTRA as a first-line treatment.
• First-Line vs. Second-Line Use: AMVUTTRA is gaining traction in both first-line and second-line settings, with a balanced uptake noted.
• Ex-U.S. Pricing: Ongoing negotiations in Europe, with expectations for modest contributions from international markets until 2026.
• Market Growth: Anticipated continued acceleration in the ATTR-CM category, driven by underdiagnosis and unmet patient needs.

Overall, Alnylam Pharmaceuticals reported strong financial performance and strategic advancements in Q3 2025, with a positive outlook for continued growth, despite some challenges related to competition and regulatory scrutiny.